Published in J Immunol on September 01, 2006
Recent progress in mucosal vaccine development: potential and limitations. Nat Rev Immunol (2012) 2.65
Novel vaccine development strategies for inducing mucosal immunity. Expert Rev Vaccines (2012) 1.04
Order-disorder-order transitions mediate the activation of cholera toxin. J Mol Biol (2008) 0.99
A novel adenovirus expressing Flt3 ligand enhances mucosal immunity by inducing mature nasopharyngeal-associated lymphoreticular tissue dendritic cell migration. J Immunol (2008) 0.97
LT-IIc, a new member of the type II heat-labile enterotoxin family encoded by an Escherichia coli strain obtained from a nonmammalian host. Infect Immun (2010) 0.91
A comparative analysis of HIV-specific mucosal/systemic T cell immunity and avidity following rDNA/rFPV and poxvirus-poxvirus prime boost immunisations. Vaccine (2011) 0.91
The nasal dendritic cell-targeting Flt3 ligand as a safe adjuvant elicits effective protection against fatal pneumococcal pneumonia. Infect Immun (2011) 0.88
Dendritic cell-targeting DNA-based mucosal adjuvants for the development of mucosal vaccines. Expert Rev Vaccines (2009) 0.84
Oral-nasopharyngeal dendritic cells mediate T cell-independent IgA class switching on B-1 B cells. PLoS One (2011) 0.84
Contributions of edema factor and protective antigen to the induction of protective immunity by Bacillus anthracis edema toxin as an intranasal adjuvant. J Immunol (2010) 0.81
Rotavirus enterotoxin NSP4 has mucosal adjuvant properties. Vaccine (2010) 0.81
Intranasal DNA Vaccine for Protection against Respiratory Infectious Diseases: The Delivery Perspectives. Pharmaceutics (2014) 0.78
Polymyxins as novel and safe mucosal adjuvants to induce humoral immune responses in mice. PLoS One (2013) 0.78
Cholera toxin induces a shift from inactive to active cyclooxygenase 2 in alveolar macrophages activated by Mycobacterium bovis BCG. Infect Immun (2012) 0.75
Quantitative Proteomic Analysis of Escherichia coli Heat-Labile Toxin B Subunit (LTB) with Enterovirus 71 (EV71) Subunit VP1. Int J Mol Sci (2016) 0.75
Roles and relevance of mast cells in infection and vaccination. J Biomed Res (2015) 0.75
Detection of heat-labile Escherichia coli enterotoxin with the use of adrenal cells in tissue culture. Science (1974) 13.04
Enterotoxigenic Escherichia coli isolated from patients with severe cholera-like disease. J Infect Dis (1971) 7.10
An investigation of traveller's diarrhoea. Lancet (1970) 4.99
Strong adjuvant properties of cholera toxin on gut mucosal immune responses to orally presented antigens. Immunology (1986) 3.28
Dissociation of Escherichia coli heat-labile enterotoxin adjuvanticity from ADP-ribosyltransferase activity. Infect Immun (1995) 3.22
Adjuvant activity of Escherichia coli heat-labile enterotoxin and effect on the induction of oral tolerance in mice to unrelated protein antigens. Vaccine (1988) 3.00
Mucosal adjuvant effect of cholera toxin in mice results from induction of T helper 2 (Th2) cells and IL-4. J Immunol (1995) 2.87
Mutants of Escherichia coli heat-labile toxin lacking ADP-ribosyltransferase activity act as nontoxic, mucosal adjuvants. Proc Natl Acad Sci U S A (1995) 2.63
Helper T cell subsets for immunoglobulin A responses: oral immunization with tetanus toxoid and cholera toxin as adjuvant selectively induces Th2 cells in mucosa associated tissues. J Exp Med (1993) 2.62
Purification and partial characterization of heat-stable enterotoxin of enterotoxigenic Escherichia coli. Infect Immun (1979) 2.55
The adjuvant effect of Vibrio cholerae and Escherichia coli heat-labile enterotoxins is linked to their ADP-ribosyltransferase activity. Eur J Immunol (1992) 2.52
Cholera toxin feeding did not induce oral tolerance in mice and abrogated oral tolerance to an unrelated protein antigen. J Immunol (1984) 2.51
Induction of antigen-specific antibodies in vaginal secretions by using a nontoxic mutant of heat-labile enterotoxin as a mucosal adjuvant. Infect Immun (1996) 2.14
A nontoxic mutant of cholera toxin elicits Th2-type responses for enhanced mucosal immunity. Proc Natl Acad Sci U S A (1997) 2.07
Cutting edge: the mucosal adjuvant cholera toxin redirects vaccine proteins into olfactory tissues. J Immunol (2000) 2.06
Mucosal adjuvanticity and immunogenicity of LTR72, a novel mutant of Escherichia coli heat-labile enterotoxin with partial knockout of ADP-ribosyltransferase activity. J Exp Med (1998) 1.98
Targeting of cholera toxin and Escherichia coli heat labile toxin in polarized epithelia: role of COOH-terminal KDEL. J Cell Biol (1995) 1.86
A genetically detoxified derivative of heat-labile Escherichia coli enterotoxin induces neutralizing antibodies against the A subunit. J Exp Med (1994) 1.68
Impact of aging on gastrointestinal mucosal immunity. Dig Dis Sci (1996) 1.63
Mutants in the ADP-ribosyltransferase cleft of cholera toxin lack diarrheagenicity but retain adjuvanticity. J Exp Med (1997) 1.61
KDEL receptor (Erd2p)-mediated retrograde transport of the cholera toxin A subunit from the Golgi involves COPI, p23, and the COOH terminus of Erd2p. J Cell Biol (1998) 1.59
Transport of an external Lys-Asp-Glu-Leu (KDEL) protein from the plasma membrane to the endoplasmic reticulum: studies with cholera toxin in Vero cells. J Cell Biol (1996) 1.57
Adjuvant activity of the heat-labile enterotoxin from enterotoxigenic Escherichia coli for oral administration of inactivated influenza virus vaccine. J Infect Dis (1997) 1.51
Mucosal immunisation and adjuvants: a brief overview of recent advances and challenges. Vaccine (2003) 1.49
Transport of bacterial lipopolysaccharide to the golgi apparatus. J Exp Med (1999) 1.45
Acceleration of influenza virus clearance by Th1 cells in the nasal site of mice immunized intranasally with adjuvant-combined recombinant nucleoprotein. J Immunol (1996) 1.37
gamma/delta T cell-deficient mice have impaired mucosal immunoglobulin A responses. J Exp Med (1996) 1.35
Induction of antibody-secreting cells and T-helper and memory cells in murine nasal lymphoid tissue. Immunology (1996) 1.31
ER-Tracker dye and BODIPY-brefeldin A differentiate the endoplasmic reticulum and golgi bodies from the tubular-vacuole system in living hyphae of Pisolithus tinctorius. J Microsc (2000) 1.23
A nontoxic adjuvant for mucosal immunity to pneumococcal surface protein A. J Immunol (1998) 1.21
Simple method of purification of Escherichia coli heat-labile enterotoxin and cholera toxin using immobilized galactose. Microb Pathog (1994) 1.21
Construction of nontoxic derivatives of cholera toxin and characterization of the immunological response against the A subunit. Infect Immun (1995) 1.20
Fluid accumulation in mouse ligated intestine inoculated with Clostridium perfringens enterotoxin. Appl Environ Microbiol (1979) 1.16
Enterotoxin-based mucosal adjuvants alter antigen trafficking and induce inflammatory responses in the nasal tract. Infect Immun (2005) 1.15
Protective mucosal immunity in aging is associated with functional CD4+ T cells in nasopharyngeal-associated lymphoreticular tissue. J Immunol (2003) 1.09
Nasal immune system: distinctive Th0 and Th1/Th2 type environments in murine nasal-associated lymphoid tissues and nasal passage, respectively. Eur J Immunol (1998) 1.07
Characterization of mouse nasal lymphocytes isolated by enzymatic extraction with collagenase. J Immunol Methods (1995) 1.06
Mutants of the Escherichia coli heat-labile enterotoxin with reduced ADP-ribosylation activity or no activity retain the immunogenic properties of the native holotoxin. Infect Immun (1996) 1.06
A nontoxic chimeric enterotoxin adjuvant induces protective immunity in both mucosal and systemic compartments with reduced IgE antibodies. J Infect Dis (2002) 1.03
Effects of intranasal administration of cholera toxin (or Escherichia coli heat-labile enterotoxin) B subunits supplemented with a trace amount of the holotoxin on the brain. Vaccine (2001) 0.99
Role of a potential endoplasmic reticulum retention sequence (RDEL) and the Golgi complex in the cytotonic activity of Escherichia coli heat-labile enterotoxin. Mol Microbiol (1995) 0.98
Evidence for early aging in the mucosal immune system. J Immunol (2000) 0.97
The cholera toxin-derived CTA1-DD vaccine adjuvant administered intranasally does not cause inflammation or accumulate in the nervous tissues. J Immunol (2004) 0.97
Mucosal antibody response induced with a nasal virosome-based influenza vaccine. Vaccine (2003) 0.96
Safety and immunogenicity of intranasally administered inactivated trivalent virosome-formulated influenza vaccine containing Escherichia coli heat-labile toxin as a mucosal adjuvant. J Infect Dis (2000) 0.96
Mutants of cholera toxin as an effective and safe adjuvant for nasal influenza vaccine. Vaccine (1999) 0.93
A novel adjuvant for mucosal immunity to HIV-1 gp120 in nonhuman primates. J Immunol (2004) 0.91
Immunological principles and emerging strategies of vaccination for the elderly. J Am Geriatr Soc (1992) 0.85
Chemiluminescence immunoassay for progesterone in plasma incorporating acridinium ester labelled antigen. Ann Clin Biochem (1988) 0.77
Toxigenic Escherichia coli in infantile diarrhea in Chicago. J Lab Clin Med (1971) 0.76
A promoter-level mammalian expression atlas. Nature (2014) 6.25
Regulation of humoral and cellular gut immunity by lamina propria dendritic cells expressing Toll-like receptor 5. Nat Immunol (2008) 5.10
Innate lymphoid cells promote anatomical containment of lymphoid-resident commensal bacteria. Science (2012) 4.20
Cholera due to altered El Tor strains of Vibrio cholerae O1 in Bangladesh. J Clin Microbiol (2006) 3.60
Global dissemination of Vibrio parahaemolyticus serotype O3:K6 and its serovariants. Clin Microbiol Rev (2007) 3.36
Uptake through glycoprotein 2 of FimH(+) bacteria by M cells initiates mucosal immune response. Nature (2009) 3.18
CCR7 is critically important for migration of dendritic cells in intestinal lamina propria to mesenteric lymph nodes. J Immunol (2006) 3.04
A dominant, coordinated T regulatory cell-IgA response to the intestinal microbiota. Proc Natl Acad Sci U S A (2009) 2.77
Intestinal villous M cells: an antigen entry site in the mucosal epithelium. Proc Natl Acad Sci U S A (2004) 2.75
Identification of multiple isolated lymphoid follicles on the antimesenteric wall of the mouse small intestine. J Immunol (2002) 2.57
Role of Peyer's patches in the induction of Helicobacter pylori-induced gastritis. Proc Natl Acad Sci U S A (2007) 2.44
Rice-based oral antibody fragment prophylaxis and therapy against rotavirus infection. J Clin Invest (2013) 2.15
Emerging trends in the etiology of enteric pathogens as evidenced from an active surveillance of hospitalized diarrhoeal patients in Kolkata, India. Gut Pathog (2010) 2.14
Global distribution of measles genotypes and measles molecular epidemiology. J Infect Dis (2011) 2.03
Toll-like receptor-dependent production of IL-12p40 causes chronic enterocolitis in myeloid cell-specific Stat3-deficient mice. J Clin Invest (2003) 2.02
DNA hypermethylation contributes to incomplete synthesis of carbohydrate determinants in gastrointestinal cancer. Gastroenterology (2008) 1.83
Emergence and evolution of Vibrio cholerae O139. Proc Natl Acad Sci U S A (2003) 1.83
RANKL is necessary and sufficient to initiate development of antigen-sampling M cells in the intestinal epithelium. J Immunol (2009) 1.73
Initiation of NALT organogenesis is independent of the IL-7R, LTbetaR, and NIK signaling pathways but requires the Id2 gene and CD3(-)CD4(+)CD45(+) cells. Immunity (2002) 1.70
Prevalence of the pandemic genotype of Vibrio parahaemolyticus in Dhaka, Bangladesh, and significance of its distribution across different serotypes. J Clin Microbiol (2002) 1.70
Probiotic Bifidobacterium breve induces IL-10-producing Tr1 cells in the colon. PLoS Pathog (2012) 1.68
Indigenous opportunistic bacteria inhabit mammalian gut-associated lymphoid tissues and share a mucosal antibody-mediated symbiosis. Proc Natl Acad Sci U S A (2010) 1.67
Intracellularly expressed TLR2s and TLR4s contribution to an immunosilent environment at the ocular mucosal epithelium. J Immunol (2004) 1.60
A dilemma for mucosal vaccination: efficacy versus toxicity using enterotoxin-based adjuvants. Vaccine (2002) 1.58
Biotyping of Vibrio cholerae O1: time to redefine the scheme. Indian J Med Res (2008) 1.58
Comprehensive gene expression profiling of Peyer's patch M cells, villous M-like cells, and intestinal epithelial cells. J Immunol (2008) 1.58
Genetic characteristics of Matlab variants of Vibrio cholerae O1 that are hybrids between classical and El Tor biotypes. J Med Microbiol (2006) 1.55
Association between involuntary smoking and salivary markers related to periodontitis: a 2-year longitudinal study. J Periodontol (2008) 1.54
Classical ctxB in Vibrio cholerae O1, Kolkata, India. Emerg Infect Dis (2009) 1.53
Evaluation of a rapid immunochromatographic dipstick kit for diagnosis of cholera emphasizes its outbreak utility. Jpn J Infect Dis (2010) 1.52
Rice-based mucosal vaccine as a global strategy for cold-chain- and needle-free vaccination. Proc Natl Acad Sci U S A (2007) 1.51
Mucosal immunosenescence: new developments and vaccines to control infectious diseases. Trends Immunol (2009) 1.49
Probiotic bifidobacteria protect mice from lethal infection with Shiga toxin-producing Escherichia coli O157:H7. Infect Immun (2004) 1.48
A novel M cell-specific carbohydrate-targeted mucosal vaccine effectively induces antigen-specific immune responses. J Exp Med (2007) 1.47
Triggering of TLR3 by polyI:C in human corneal epithelial cells to induce inflammatory cytokines. Biochem Biophys Res Commun (2005) 1.46
Nanogel antigenic protein-delivery system for adjuvant-free intranasal vaccines. Nat Mater (2010) 1.45
Establishment of a poliovirus oral infection system in human poliovirus receptor-expressing transgenic mice that are deficient in alpha/beta interferon receptor. J Virol (2007) 1.40
Vibrio cholerae O139 Bengal: odyssey of a fortuitous variant. Microbes Infect (2003) 1.40
Specific expression of apolipoprotein A-IV in the follicle-associated epithelium of the small intestine. Dig Dis Sci (2014) 1.38
Dysbiosis of salivary microbiota in inflammatory bowel disease and its association with oral immunological biomarkers. DNA Res (2013) 1.38
Diverse CTX phages among toxigenic Vibrio cholerae O1 and O139 strains isolated between 1994 and 2002 in an area where cholera is endemic in Bangladesh. J Clin Microbiol (2004) 1.37
Forced usage of positively charged amino acids in immunoglobulin CDR-H3 impairs B cell development and antibody production. J Exp Med (2006) 1.36
New generation of mucosal adjuvants for the induction of protective immunity. Rev Med Virol (2003) 1.34
Effective mucosal immunity to anthrax: neutralizing antibodies and Th cell responses following nasal immunization with protective antigen. J Immunol (2003) 1.34
Escalating association of Vibrio cholerae O139 with cholera outbreaks in India. J Clin Microbiol (2002) 1.33
A Tecpr1-dependent selective autophagy pathway targets bacterial pathogens. Cell Host Microbe (2011) 1.31
IL-15-dependent activation-induced cell death-resistant Th1 type CD8 alpha beta+NK1.1+ T cells for the development of small intestinal inflammation. J Immunol (2002) 1.30
IL-15 triggers an antiapoptotic pathway in human intraepithelial lymphocytes that is a potential new target in celiac disease-associated inflammation and lymphomagenesis. J Clin Invest (2010) 1.28
Prevalence and genetic profiling of virulence determinants of non-O157 Shiga toxin-producing Escherichia coli isolated from cattle, beef, and humans, Calcutta, India. Emerg Infect Dis (2002) 1.27
Clonal multidrug-resistant Shigella dysenteriae type 1 strains associated with epidemic and sporadic dysenteries in eastern India. Antimicrob Agents Chemother (2004) 1.27
Epithelial barrier: an interface for the cross-communication between gut flora and immune system. Immunol Rev (2012) 1.27
Molecular analysis of the rstR and orfU genes of the CTX prophages integrated in the small chromosomes of environmental Vibrio cholerae non-O1, non-O139 strains. Environ Microbiol (2006) 1.27
Development of mature and functional human myeloid subsets in hematopoietic stem cell-engrafted NOD/SCID/IL2rγKO mice. J Immunol (2012) 1.27
A rice-based edible vaccine expressing multiple T cell epitopes induces oral tolerance for inhibition of Th2-mediated IgE responses. Proc Natl Acad Sci U S A (2005) 1.24
Membrane-bound human SCF/KL promotes in vivo human hematopoietic engraftment and myeloid differentiation. Blood (2012) 1.23
Diarrheagenic pathogens in polymicrobial infections. Emerg Infect Dis (2011) 1.22
MIP-1alpha and MIP-1beta differentially mediate mucosal and systemic adaptive immunity. Blood (2002) 1.21
IFN-gamma-inducible chemokines enhance adaptive immunity and colitis. J Interferon Cytokine Res (2003) 1.21
Intestinal lamina propria retaining CD4+CD25+ regulatory T cells is a suppressive site of intestinal inflammation. J Immunol (2007) 1.21
Isolation of Shigella dysenteriae type 1 and S. flexneri strains from surface waters in Bangladesh: comparative molecular analysis of environmental Shigella isolates versus clinical strains. Appl Environ Microbiol (2002) 1.20
Pneumococcal carriage results in ganglioside-mediated olfactory tissue infection. Proc Natl Acad Sci U S A (2003) 1.19
Visualization of microtubule-mediated transport of influenza viral progeny ribonucleoprotein. Microbes Infect (2007) 1.19
Extracellular ATP mediates mast cell-dependent intestinal inflammation through P2X7 purinoceptors. Nat Commun (2012) 1.18
IgA class switch occurs in the organized nasopharynx- and gut-associated lymphoid tissue, but not in the diffuse lamina propria of airways and gut. J Immunol (2004) 1.18
HIV infection: first battle decides the war. Trends Immunol (2006) 1.15
Enterotoxin-based mucosal adjuvants alter antigen trafficking and induce inflammatory responses in the nasal tract. Infect Immun (2005) 1.15
Lethal canine distemper virus outbreak in cynomolgus monkeys in Japan in 2008. J Virol (2012) 1.14
Sphingosine 1-phosphate-mediated trafficking of pathogenic Th2 and mast cells for the control of food allergy. J Immunol (2007) 1.14
Development and evaluation of a PCR assay for tracking the emergence and dissemination of Haitian variant ctxB in Vibrio cholerae O1 strains isolated from Kolkata, India. J Clin Microbiol (2012) 1.13
Sphingosine 1-phosphate dependence in the regulation of lymphocyte trafficking to the gut epithelium. J Exp Med (2007) 1.13
Bacterial exotoxins downregulate cathelicidin (hCAP-18/LL-37) and human beta-defensin 1 (HBD-1) expression in the intestinal epithelial cells. Cell Microbiol (2008) 1.13
Multidrug-resistant Shigella dysenteriae type 1: forerunners of a new epidemic strain in eastern India? Emerg Infect Dis (2003) 1.12
Secretory IgA-mediated protection against V. cholerae and heat-labile enterotoxin-producing enterotoxigenic Escherichia coli by rice-based vaccine. Proc Natl Acad Sci U S A (2010) 1.11
Inhibition of CCL1-CCR8 interaction prevents aggregation of macrophages and development of peritoneal adhesions. J Immunol (2007) 1.11
Protective mucosal immunity in aging is associated with functional CD4+ T cells in nasopharyngeal-associated lymphoreticular tissue. J Immunol (2003) 1.09
An essential role for the N-terminal fragment of Toll-like receptor 9 in DNA sensing. Nat Commun (2013) 1.09
Mucosal vaccines: novel advances in technology and delivery. Expert Rev Vaccines (2009) 1.09
Role of gut-associated lymphoreticular tissues in antigen-specific intestinal IgA immunity. J Immunol (2004) 1.08
Sphingosine 1-phosphate regulates peritoneal B-cell trafficking for subsequent intestinal IgA production. Blood (2007) 1.08
Rubella virus as a possible etiological agent of Fuchs heterochromic iridocyclitis. Graefes Arch Clin Exp Ophthalmol (2010) 1.07
Therapeutic potential of follistatin for colonic inflammation in mice. Gastroenterology (2005) 1.07
Intraepithelial lymphocytes: their shared and divergent immunological behaviors in the small and large intestine. Immunol Rev (2007) 1.07
Oral immunization: an update. Curr Opin Gastroenterol (2008) 1.06
Status of global virologic surveillance for rubella viruses. J Infect Dis (2011) 1.06